versus 138
Sale Price:$333.00
Original Price:$999.00
sale
Allocation to sacubitril/valsartan had no significant effect on fatal serious adverse events (1 [0.5%] versus 1 [0.5%]) or on any nonfatal serious adverse events (61 [29.5%] versus 59 [28.5%]; rate ratio, 1.07; 95% CI, 0.75–1.53; P=0.70) (Table IV in the online-only Data Supplement). One case of angioedema occurred in a participant allocated ... rtp atom 138
Quantity: